MOSPD2

Across TCGA pan-cancer cohorts, MOSPD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MOSPD2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MOSPD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MOSPD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

UCEC, GBM, and PDAC are the cancer types where MOSPD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	1.000	0.609	.008	16	view →
GBM	OS	Tertile	All	0.418	0.613	.009	11	view →
PDAC	DFS	Quartile	All	0.709	0.859	.010	6	view →
CCRCC	OS	Median	All	1.000	0.911	.023	5	view →
LUAD	DFS	Tertile	All	0.576	0.813	.007	4	view →
LSCC	DFS	Tertile	II,III,IV	0.999	0.830	.020	3	view →
HNSC	DFS	Quartile	III,IV	0.695	0.897	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MOSPD2–UCEC (OS)

Open the UCEC breakdown →